Randomized Clinical Trial of Surgical vs. Percutaneous vs. Hybrid Revascularization in Multivessel Coronary Artery Disease: Residual Myocardial Ischemia and Clinical Outcomes at One Year—Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS)

Table 2

HREVS study endpoints according to randomization group.

Endpoint	CABG	HCR	PCI	value
Primary endpoint at 12 months
	N = 49	N = 49	N = 51
RI (SPECT)	6.7 (4.6, 8.8)	6.4 (4.3, 8.5)	7.9 (5.9, 9.8)	0.45
Secondary endpoints at 12 months
	N = 50	N = 52	N = 53
MACCE (death/stroke/MI/clinically driven repeat revascularization)	12.0% (6)	13.4% (7)	13.2% (7)	0.83
Death	2.0% (1)	5.8% (3)	3.8% (2)	0.78
Stroke	0% (0)	3.8% (2)	0% (0)	0.21
MI	8% (4)	5.8% (3)	7.5% (4)	0.66
Clinically driven TVR	2.0% (1)	1.9% (1)	5.7% (3)	0.54
Angiography-driven TVR	2.0% (1)	11.5% (6)	11.3% (6)	0.139
Total TVR	4.0% (2)	13.5% (7)	17.0% (9)	0.095
Secondary endpoints at 30 days
MACCE (death/stroke/MI/clinically driven repeat revascularization)	8% (4)	5.8% (3)	3.8% (2)	0.37
Death	0% (0)	1.9% (1)	0% (0)	0.66
Stroke	0% (0)	1.9% (1)	0% (0)	0.66
MI	8% (4)	5.8% (3)	3.8% (2)	0.37
Repeat revascularization	0% (0)	1.9% (1)	0% (0)	0.66
Conversion to CABG	NA	9.6% (5)	0	0.027
Bleeding
BARC 0–1	80.0% (40)	80.8% (42)	98.1% (52)
BARC 2	0% (0)	9.6% (5)	1.9% (1)
BARC 3–4	20.0% (10)	9.6% (5)	0% (0)	0.001
Hospital stay (days)	13.8 (12.5, 15.1)	13.5 (12.2, 14.8)	4.5 (3.2, 5.8)	<0.001
Institutional rehabilitation	100% (49)	97.9% (48)	56.8% (29)	<0.001
Sick leave (weeks)	23 (21, 25)	16 (15, 18)	8 (6, 10)	<0.001

Data are presented as means (95% confidence interval) or percentages (counts). Evaluable in patients alive at 12 ± 1 months. on combined noninferiority analysis that the study was powered for (cf. Figure 1).